Antihypertensive comparison of furosemide with hydrochlorothiazide for black patients.
Furosemide and hydrochlorothiazide were compared for treatment of black patients with mild to moderate hypertension in a randomized, open-label, crossover study design. Hydrochlorothiazide produced a significantly greater fall in mean arterial (24.7 vs 16.0 mm Hg, P less than .01) and diastolic (17.3 vs 10.1 mm Hg, P less than .01) blood pressure (BP) in 16 patients. Addition of methyldopa in nine patients produced a significantly greater fall in mean arterial (38.8 vs 31.9 mm Hg, P less than .05) and diastolic (28.9 vs 23.4 mm Hg, P less than .05) BP with hydrochlorothiazide vs furosemide. Renin status was categorized before and after treatment. Patients with low and normal renin activity were equally responsive to both diuretics. Hydrochlorothiazide caused a greater reduction in plasma potassium (0.26 mEg/L). Serum parathyroid hormone was not chronically elevated with furosemide. In this study, hydrochlorothiazide was more effective than furosemide for treatment of mild to moderate hypertension in black patients; renin classification did not predict diuretic responsiveness.
D000328:Adult; D001741:Black or African American; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010919:Placebos; D011188:Potassium / Q000097:blood; D012083:Renin / Q000097:blood
D010281:Parathyroid Hormone; D010919:Placebos; D006852:Hydrochlorothiazide; D008750:Methyldopa; D005665:Furosemide; D012083:Renin; D011188:Potassium